Deals channel feed

Go­ing against the cur­rent, Sor­ren­to spins out pain-fo­cused sub­sidiary in $140M SPAC deal

4 years ago

Bust­ed in the wake of a CRL, Athenex brings out bud­get axe af­ter 'go­ing con­cern' alert

4 years ago

Sanofi part­ners up with dom­i­nant ADC play­er Seagen, dou­bling down on on­col­o­gy in hunt for a bet­ter pipeline

4 years ago
R&D

No­vo Nordisk ‘think­ing big’ in re­newed col­lab­o­ra­tion with high-pro­file sci­en­tists Tra­ver­so, Langer

4 years ago

As San­doz waits for No­var­tis to de­ter­mine its fate, the gener­ics play­er buys out a res­pi­ra­to­ry de­vice com­pa­ny

4 years ago
Pharma

Green­Light li­cens­es mR­NA shin­gles vac­cine to Serum In­sti­tute fol­low­ing a $10M in­vest­ment

4 years ago
Pharma
Manufacturing

With a make-or-break PhI­II read­out loom­ing, a strug­gling Con­cert of­floads a 'port­fo­lio' of drugs

4 years ago

Fol­low­ing Vray­lar suc­cess, Ab­b­Vie ex­tends part­ner­ship with Gedeon Richter to neu­ropsy­chi­atric dis­eases

4 years ago
Pharma

Pfiz­er com­pletes $6.7B Are­na deal af­ter clock runs out on FTC ob­jec­tion pe­ri­od

4 years ago

Mor­phoSys sends its Con­stel­la­tion drug work to Ger­many, shut­ter­ing US R&D and tak­ing a $250M hit in re­or­ga­ni­za­tion

4 years ago
R&D

J&J ex­pands deal with lit­tle-known Welsh biotech us­ing 3D print­ing to bet­ter en­cap­su­late drugs

4 years ago

BioN­Tech and Re­gen­eron ex­pand their can­cer part­ner­ship, push­ing new Lib­tayo com­bo in­to NSCLC

4 years ago

No­var­tis takes a gam­ble on Voy­ager's new AAV tech, inks $1.7B gene ther­a­py dis­cov­ery pact

4 years ago
Cell/Gene Tx

So, just how much are those CRISPR patents ac­tu­al­ly worth?

4 years ago
Cell/Gene Tx

Sanofi inks an al­liance pact with chron­ic dis­ease-fo­cused dig­i­tal ther­a­peu­tics play­er

4 years ago
Pharma

Sanofi en­lists Ada­gene and its 'mask­ing' tech to de­vel­op new I/O drugs, in a deal po­ten­tial­ly worth $2.5B

4 years ago

Bris­tol My­ers part­ner comes through on IL-12 ef­fort. Now it's Ru­pert Vessey's turn at bat

4 years ago
R&D

Ab­b­Vie adds to its neu­ro pipeline with a $1B buy­out deal, bolt­ing on a new drug aimed at Alzheimer’s

4 years ago

In the wake of pa­tient death, Sutro says its Chi­nese part­ner is re­think­ing their deal and with­hold­ing $40M

4 years ago

Blue­print part­ners up with a de­grad­er-fo­cused 'van­t' as part of pipeline-boost­ing cam­paign

4 years ago

In all-en­com­pass­ing rights deal with Huadong, Di­et­mar Hop­p's Hei­del­berg looks to bring its AD­Cs to most of Asia

4 years ago

Biosim­i­lars unite: Look­ing for com­mer­cial con­sol­i­da­tion, Bio­con buys out long­time part­ner Vi­a­tris for $3.3B

4 years ago

In two sep­a­rate moves, Bio­haven seeks to re­pur­pose failed Bris­tol My­ers/Roche Duchenne drug while buy­ing out small biotech

4 years ago

Am­i­cus and Per­cep­tive call off SPAC merg­er for gene ther­a­py spin­out af­ter re­cent set­back

4 years ago
First page Previous page 61626364656667 Next page Last page
A service from the Financial Times